Established in the year 2010, Oncotarget is an open access medical journal covering all aspects of Oncology. Oncotarget has managed to employ highly recognized editors, Mikhail Blagosklonny and Andrei V. Gudkov. The journal is reviewed on a weekly basis and through this maintains insightfulness and punctuality, while maintaining a constructive impact of their research readily available to all researchers.
Oncotarget’s impact factor, Thomson Reuters, was at an all-time high in 2012 through 2014 at an average of 6.5-percent. They have leveled out at around 5.4 by 2016, but are expecting another rise in early 2017. Oncotarget is also available on Dove Press.
The Editor in Chief of Oncotarget has a plethora of experience related to cancer and anti-aging. Mikhail obtained a Medical Degree in internal medicine from the First Pavlov State Medical University of St. Petersburg, then went on to earn his Doctorate of Philosophy in experimental medicine and cardiology from the same university. In 2002 he was named the associate professor of medicine for the New York Medical College. Mikhail joined the Roswell Park Cancer Institute as a Professor of Oncology in 2009.
Through his impressive education and professional background, and his research in Biogerontology and Cancer, anti-aging drugs and cancer targeting therapies to help guard the remaining healthy cells against getting damaged is how he obtained his current position as Oncotarget’s Editor-in Chief.
In addition to all other accomplishments Mikhail Blagosklonny has achieved he is also an author in the fields of Hyperfunction Theory, Cyclotherapy and chemotherapeutic engineering. He truly believes that not only the aging process but cancer as well are fully controllable.
Mikhails belief in a disease free civilization continuously drives him and his team at Oncotarget to maintain constant improvement, to better serve the researchers who deppend so much on them to do their jobs. They have chosen to sacrifice so much in hope of helping us all one day be able to live without the fear of disease. Follow Oncotarget journal on Twitter.